“An emerging approach to the treatment of chronic musculoskeletal pain is the harvest and concentration/isolation of autologous mesenchymal stem cells (MSCs) for reinjection into damaged or degenerated joints, ligaments, tendons and muscles.” MSCs have been dubbed “patient-specific drug stores for injured tissues” because of their ability to secrete bioactive factors and signals at variable concentrations in response to local microenvironmental cues.”